Cefuroxime Axetil + Clavulanic Acid

Presentation

• Ximeclav 250 tablet: Each film-coated tablet contains Cefuroxime 250 mg as Cefuroxime Axetil USP and Clavulanic Acid 62.5 mg as Clavulanate Potassium BP.
• Ximeclav 500 tablet: Each film-coated tablet contains Cefuroxime 500 mg as Cefuroxime Axetil USP and Clavulanic Acid 125 mg as Clavulanate Potassium BP.
• Ximeclav Powder for Suspension: Each 5 ml reconstituted suspension contains Cefuroxime 125 mg as Cefuroxime Axetil USP and Clavulanic Acid 31.25 mg as Clavulanate Potassium BP.

 

 Descriptions

Cefuroxime is a second-generation, beta-lactam, bactericidal, cephalosporin antibiotic. Cefuroxime is active against a wide range of Gram (+) ve and Gram (-) ve susceptible bacteria. Clavulanic acid is structurally similar to beta-lactam antibiotics & exhibits negligible antibacterial activity. Clavulanic acid acts as a β-lactamase inhibitor by binding irreversibly to β-lactamase enzymes.

The presence of clavulanic acid in Ximeclav formulation protects the effectiveness of Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to many bacteria normally resistant to Cefuroxime and other cephalosporins.

 

Indications: Ximeclav is indicated for –

• Pharyngitis/Tonsillitis
• Acute Bacterial Otitis Media
• Acute Bacterial Maxillary Sinusitis
• Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis
• Uncomplicated Skin and Skin-Structure Infections.
• Uncomplicated Urinary Tract Infections

 

Therapeutic Class

Antibiotic, 2^nd generation Cephalosporin with Clavulanic Acid

Prescribing Information